Resolvin D2 (RvD2, 7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid) is a specialized pro-resolving mediator biosynthesized from DHA through sequential lipoxygenase reactions. It signals exclusively through the DRV2/GPR18 receptor to actively orchestrate inflammatory resolution, distinguishing it from RvD1 which uses different receptor pathways. RvD2 operates in the nanomolar range to coordinate neutrophil clearance, enhance Efferocytosis, and promote tissue repair without suppressing antimicrobial defense.
Think of RvD2 as a specialized cleanup crew supervisor at a construction site accident. While RvD1 is the first supervisor who arrives and starts directing traffic through one set of walkie-talkie channels, RvD2 shows up with a completely different radio frequency (GPR18) that reaches additional crew members the first supervisor can't contact. RvD2's unique frequency allows it to tell the demolition workers (neutrophils) "your shift is over, time to pack up safely" while simultaneously instructing the cleanup crew (macrophages) to "come eat the leftover debris efficiently." Critically, RvD2 doesn't tell the security guards (antibacterial defenses) to go home—it just makes sure the construction mess gets cleaned up properly so the site can return to normal function. The crew can only do this job if the company has enough raw materials (DHA) in the warehouse to make the specialized radios in the first place.
RvD2 biosynthesis follows a stereospecific enzymatic cascade:
Biosynthetic Pathway:
- DHA (22:6 omega-3) is released from membrane phospholipids by phospholipase A2
- 15-LOX (15-lipoxygenase) converts DHA → 17S-hydroperoxy-DHA (17S-HpDHA)
- 5-LOX (5-lipoxygenase) converts 17S-HpDHA → 7S,17S-dihydroxy-DHA intermediate
- Additional hydroxylation at carbon-16 → 7S,16R,17S-trihydroxy-DHA (RvD2)
Receptor Signaling:
RvD2 → GPR18 (DRV2/GPR18 receptor) → Gi protein activation → ↓cAMP → multiple downstream cascades:
graph TD
A[RvD2] --> B[GPR18 Receptor]
B --> C[Gi Protein Activation]
C --> D["↓ cAMP"]
D --> E[PKA Inhibition]
E --> F[Reduced Pro-inflammatory Gene Transcription]
C --> G[PI3K/AKT Activation]
G --> H[Enhanced Phagocyte Function]
H --> I[Increased Efferocytosis]
C --> J[ERK1/2 Pathway]
J --> K[Neutrophil Apoptosis Programs]
K --> L[Reduced Tissue Damage]
B --> M[STAT3 Activation]
M --> N[IL-10 Production]
N --> O[Anti-inflammatory Milieu]
Cellular Effects:
- Neutrophils: RvD2-GPR18 → apoptosis signaling → phosphatidylserine externalization → "eat-me" signals → ↓ neutrophil lifespan from ~24h to 8-12h
- Macrophages: RvD2 → enhanced phagocytic capacity → ↑ CD36 expression → efficient apoptotic cell clearance → ↑ IL-10/↓ IL-12 secretion
- Epithelial cells: RvD2 → ↑ antimicrobial peptide production (maintaining host defense) + ↑ wound healing mediators (TGF-β, VEGF)
- T cells: RvD2 → limits Th1/Th17 differentiation → promotes regulatory T cell (Treg) development
Receptor Specificity:
Unlike RvD1 (which signals through ALX/FPR2 and GPR32), RvD2 exclusively uses GPR18, allowing independent and complementary resolution programs. This means DHA can generate multiple resolution signals with non-overlapping mechanisms.
Metabolic Inactivation:
RvD2 is dehydrogenated by Eicosanoid oxidoreductase (E15-PGDH) → loss of bioactivity → allowing temporal control of resolution phase duration.
Clinical Contexts:
- Sepsis: RvD2 administration in preclinical models reduces mortality by enhancing bacterial clearance while limiting cytokine storm—GPR18 activation coordinates effective antimicrobial response with controlled inflammation
- Acute Respiratory Distress Syndrome (ARDS): RvD2 accelerates resolution of pulmonary inflammation, reducing alveolar neutrophil accumulation and promoting epithelial repair (relevant for COVID-19, Influenza complications)
- Chronic Pain: RvD2 exhibits analgesic properties through GPR18 signaling in dorsal root ganglia, reducing neuroinflammation-driven central sensitization—distinct from opioid mechanisms
- Inflammatory Bowel Disease: RvD2 production is deficient in Crohn's disease and Ulcerative Colitis patients; GPR18 agonism represents novel therapeutic target
Metamodel Integration:
- Metamodel 3 (Evolutionary Mismatch): Modern Omega-3 fatty acids depletion (omega-6/omega-3 ratios of 15-20:1 vs ancestral 1-2:1) reduces RvD2 substrate availability, creating "resolution deficit" that perpetuates chronic inflammation
- Selfish Immune System: RvD2 represents immune system's self-limiting mechanism—when DHA depleted, immune system lacks brake pedal, leading to immunological set points favoring chronic activation
- Resolution Pharmacology: Unlike immunosuppressants, RvD2 enhances resolution while maintaining host defense—therapeutic window for "resolution-first" rather than "suppress-first" strategies
Biomarkers & Thresholds:
- RvD2 plasma levels <0.5 ng/mL associated with delayed resolution in surgical patients
- Omega-3 index <4% correlates with impaired RvD2 biosynthesis capacity
- GPR18 expression downregulated in chronic inflammatory tissues (providing mechanism for resolution failure)
- Resolution interval (R_i) shortened by 40-60% in presence of adequate RvD2 signaling
Intervention Implications:
- DHA Supplementation: 2-4g EPA+DHA daily increases RvD2 precursor pool (requires 4-6 weeks to saturate membrane phospholipids)
- Aspirin Coadministration: Acetylated COX-2 produces aspirin-triggered resolvins from EPA but NOT DHA-derived resolvins—RvD2 pathway aspirin-independent
- Receptor Agonist Development: GPR18-selective agonists under development as "resolution pharmacology" drugs
- Clinical Timing: RvD2 most effective when administered during early-to-mid inflammatory phase (24-48h post-injury), not prophylactically
- RvD2 has stereospecific 7S,16R,17S hydroxyl configuration—chirality critical for GPR18 binding (wrong stereoisomer inactive)
- Active concentration range: 0.1-10 nM (picomolar to low nanomolar)—far more potent than most cytokines
- GPR18 (DRV2) is G-protein coupled receptor structurally distinct from RvD1 receptors (ALX/FPR2, GPR32)
- RvD2 half-life in vivo: approximately 15-20 minutes (rapid action, rapid clearance)
- Reduces neutrophil infiltration by 40-70% in murine peritonitis models
- Enhances macrophage phagocytosis of apoptotic cells 3-5 fold at 10 nM concentration
- Does NOT suppress bacterial killing—maintains or enhances antimicrobial peptide production
- Produced locally at inflammation sites from circulating DHA—requires adequate omega-3 status
- GPR18 expression highest in spleen, thymus, peripheral leukocytes, brain (microglia)
- RvD2 production peaks 12-24 hours after inflammatory stimulus in healthy resolution (coinciding with Lipid mediator class switching)
- DHA — RvD2 is biosynthesized exclusively from DHA through lipoxygenase pathways; DHA depletion prevents RvD2 formation
- 15-LOX — initiates RvD2 biosynthesis by converting DHA to 17S-hydroperoxy-DHA
- 5-LOX — completes RvD2 biosynthesis by adding 7S-hydroxyl group
- GPR18 — exclusive receptor for RvD2, mediating all cellular resolution signals
- Specialized pro-resolving mediators (SPMs) — RvD2 is core member of SPM family with unique receptor profile
- RvD1 — related D-series resolvin with different receptor specificity (ALX/FPR2, GPR32), providing complementary actions
- Resolvin D-series — RvD2 is second identified member (after RvD1), includes RvD3-RvD6 with distinct structures
- Resolution of inflammation — RvD2 actively drives resolution phase rather than passive decay of inflammation
- Efferocytosis — RvD2 enhances macrophage clearance of apoptotic neutrophils via GPR18-dependent phagocytosis
- Neutrophil — RvD2 promotes neutrophil apoptosis and prevents further tissue infiltration
- Lipid mediator class switching — RvD2 production represents switch from pro-inflammatory eicosanoids to pro-resolving lipid mediators
- Resolution interval (R_i) — RvD2 shortens R_i by accelerating neutrophil clearance and debris removal
- Omega-3 fatty acids — adequate omega-3 intake essential for RvD2 substrate availability
- Macrophage Polarization — RvD2 promotes M2-like resolution phenotype while maintaining antimicrobial capacity
- Chronic inflammation — RvD2 deficiency contributes to failed resolution and chronic inflammatory states
- COX-2 — COX-2 produces prostaglandins early in inflammation; lipid mediator class switching shifts to RvD2 production
- IL-10 — RvD2 signaling upregulates IL-10 production, reinforcing anti-inflammatory environment
- Acute inflammatory response — RvD2 appears during resolution phase (12-48h) to orchestrate inflammation termination
- Sepsis — RvD2 reduces sepsis mortality in preclinical models by balancing pathogen clearance with inflammation control
- Inflammatory Bowel Disease — IBD patients show reduced RvD2 levels correlating with chronic mucosal inflammation
- EPA — both EPA and DHA generate resolvins, but RvD2 is DHA-specific (EPA generates E-series resolvins)
- Resoleomics — RvD2 measurement part of comprehensive SPM profiling to assess resolution capacity